coming off glp 1 side effects Why do patients stop GLP-1 drugs? Yes, there is a downside

The Ominous Octet Over the last 30 years our understanding of the pathophysiology of T2DM has revealed that the disease is more complicated than previously appreciated with at least 8 distinct pathogenic abnormalities which collectively comprise the OMINOUS OCTET (2) (Figure 1)

The approach could begin by prioritizing treatment for patients most likely to benefit from GLP-1 drugs to reach specific weight loss targets

The three biggest sources of waste are: Poor storage: Leaving reconstituted vials at room temperature accelerates degradation

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

GLP1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NFkappaB signaling pathways in streptozotocininduced diabetic rats